Davide Carcione
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Davide Carcione has a total of 175 co-authors. Here are the top co-authors by number of shared publications:
- Jari Intra
Clinical Chemistry Laboratory, Fondazione IRCCS San Gerardo dei Tintori
9 shared publications - Luigi Principe
Microbiology and Virology Unit, Great Metropolitan Hospital “Bianchi-Melacrino-Morelli”, 89100 Reggio Calabria, Italy
6 shared publications - Stefano Di Bella
Clinical Department of Medical, Surgical and Health Sciences Trieste University Trieste Italy
5 shared publications - Valerio Leoni
Laboratory of Clinical Pathology and Toxicology, Hospital Pio XI of Desio, ASST Brianza and School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
4 shared publications - Claudia Siracusa
Department of Laboratory Medicine, University of Milano-Bicocca, Azienda Socio Sanitaria Territoriale Brianza ASST-Brianza, Desio Hospital, Via Mazzini 1, 20833 Desio, Italy
3 shared publications - Floriana Campanile
Department of Biomedical and Biotechnological Sciences, Section of Microbiology, University of Catania, 95123 Catania, Italy
3 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (10) , 2203
A Comprehensive Review of the Underlying Mechanisms of Resistance and Therapeutic Options for DTR-PA in Bloodstream Infection and Pneumonia: A Clinical Vignette-Based Approach
Pseudomonas aeruginosa is a ubiquitous opportunistic pathogen and a leading cause of severe healthcare-associated infections, particularly ventilator-associated pneumonia (VAP) and bloodstream infections (BSIs) in critically ill patients. Its remarkable capacity for both intrinsic and acquired resistance leads to complex phenotypic profiles, culminating in difficult-to-treat resistant P. aeruginosa (DTR-PA). Managing DTR-PA presents a daunting clinical challenge characterised by a narrow therapeutic armamentarium, treatment delays, and high attributable mortality. To bridge the gap between complex molecular microbiology and bedside decision-making, this narrative review employs a pragmatic, clinical vignette-based approach. Through six representative fictional scenarios of pneumonia and BSI, we systematically dissect the underlying mechanisms of resistance and their direct therapeutic implications. The vignettes explore combinations of intrinsic adaptations—such as Pseudomonas-derived cephalosporinase (PDC/AmpC) hyperexpression, OprD porin loss, and efflux pump upregulation—as well as the acquisition of serine- (e.g., GES) and metallo-β-lactamases (e.g., VIM, NDM, IMP). Grounded in the updated 2026 Infectious Diseases Society of America (IDSA) guidelines, we evaluate the optimal deployment of newer β-lactam/β-lactamase inhibitor combinations. We highlight the specific preference for ceftolozane–tazobactam in pneumonia, the roles of ceftazidime–avibactam and imipenem–relebactam, and the critical use of cefiderocol for metallo-β-lactamase producers and highly resistant phenotypes. Furthermore, the review addresses pressing clinical controversies: the superiority of targeted monotherapy over historical, toxic combination regimens; the risks of unconditionally applying “shorter-is-better” duration paradigms to DTR-PA; and the alarming frequency of treatment-emergent cross-resistance among novel agents. We also clarify common clinical misconceptions, such as the limited utility of meropenem–vaborbactam and aztreonam–avibactam against specific pseudomonal mechanisms. Ultimately, effective DTR-PA management precludes class-based empirical assumptions. By providing a phenotype-driven bedside aide-mémoire, this review reinforces that rapid recognition, direct agent-specific antimicrobial susceptibility testing (AST), pharmacokinetic/pharmacodynamic (PK/PD)-optimised dosing, and prompt source control remain the absolute cornerstones of survival for patients afflicted by these formidable infections.
- 1 October 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (10) , 2203
Open AccessA Comprehensive Review of the Underlying Mechanisms of Resistance and Therapeutic Options for DTR-PA in Bloodstream Infection and Pneumonia: A Clinical Vignette-Based Approach
Pseudomonas aeruginosa is a ubiquitous opportunistic pathogen and a leading cause of severe healthcare-associated infections, particularly ventilator-associated pneumonia (VAP) and bloodstream infections (BSIs) in critically ill patients. Its remarkable capacity for both intrinsic and acquired resistance leads to complex phenotypic profiles, culminating in difficult-to-treat resistant P. aeruginosa (DTR-PA). Managing DTR-PA presents a daunting clinical challenge characterised by a narrow therapeutic armamentarium, treatment delays, and high attributable mortality. To bridge the gap between complex molecular microbiology and bedside decision-making, this narrative review employs a pragmatic, clinical vignette-based approach. Through six representative fictional scenarios of pneumonia and BSI, we systematically dissect the underlying mechanisms of resistance and their direct therapeutic implications. The vignettes explore combinations of intrinsic adaptations—such as Pseudomonas-derived cephalosporinase (PDC/AmpC) hyperexpression, OprD porin loss, and efflux pump upregulation—as well as the acquisition of serine- (e.g., GES) and metallo-β-lactamases (e.g., VIM, NDM, IMP). Grounded in the updated 2026 Infectious Diseases Society of America (IDSA) guidelines, we evaluate the optimal deployment of newer β-lactam/β-lactamase inhibitor combinations. We highlight the specific preference for ceftolozane–tazobactam in pneumonia, the roles of ceftazidime–avibactam and imipenem–relebactam, and the critical use of cefiderocol for metallo-β-lactamase producers and highly resistant phenotypes. Furthermore, the review addresses pressing clinical controversies: the superiority of targeted monotherapy over historical, toxic combination regimens; the risks of unconditionally applying “shorter-is-better” duration paradigms to DTR-PA; and the alarming frequency of treatment-emergent cross-resistance among novel agents. We also clarify common clinical misconceptions, such as the limited utility of meropenem–vaborbactam and aztreonam–avibactam against specific pseudomonal mechanisms. Ultimately, effective DTR-PA management precludes class-based empirical assumptions. By providing a phenotype-driven bedside aide-mémoire, this review reinforces that rapid recognition, direct agent-specific antimicrobial susceptibility testing (AST), pharmacokinetic/pharmacodynamic (PK/PD)-optimised dosing, and prompt source control remain the absolute cornerstones of survival for patients afflicted by these formidable infections.
- Open Access
- 2 March 2026
- Published by PAGEPress Publications in Microbiologia Medica
- Vol. 40 (2)
Susceptibility patterns of Streptococcus pyogenes isolated in the Italian Hospital of Desio: a 20-year (2000-2019) retrospective study
Background: Streptococcus pyogenes is a Gram-positive bacterium responsible for different infections, some of them serious and life-threatening. Increasing antimicrobial resistance trends have been observed in S. pyogenes isolates worldwide. In the present study, data of susceptibility patterns of S. pyogenes isolates were retrieved from 2000 to 2019 with the aim to observe the emergence of resistance and to guide clinicians in prescription appropriateness. Materials and Methods: we collected a total of 4,958 unique S. pyogenes strains from positive samples, out of them 4,597 (93%) were from throat swabs, followed by vaginal swabs, skin swabs, blood cultures, and ear swabs. The median age of patients was 10 years (range 0-94 years). Results: the analysis was performed on the data collected from throat samples and blood cultures. In the isolates from throat specimens, except β-lactams and glycopeptides (vancomycin) which presented 100% of susceptibility, and tetracycline which presented an average resistance rate of 26%, all the other antibiotics tested showed significant increasing resistance trends: clindamycin 13-23%, erythromycin 29-35%, and levofloxacin 5-12% (p<0.01). About susceptibilities of isolates from blood cultures, although the low number of isolates, we observed 98-100% of susceptibility. Conclusions: although this work is single-center, national and regional active surveillance projects are needed to monitor antimicrobial resistance trends of S. pyogenes, and to help physicians in antibiotic prescription in subjects affected by acute or recurrent sore throats.
- 2 March 2026
- Published by PAGEPress Publications in Microbiologia Medica
- Vol. 40 (2)
Open AccessSusceptibility patterns of Streptococcus pyogenes isolated in the Italian Hospital of Desio: a 20-year (2000-2019) retrospective study
Background: Streptococcus pyogenes is a Gram-positive bacterium responsible for different infections, some of them serious and life-threatening. Increasing antimicrobial resistance trends have been observed in S. pyogenes isolates worldwide. In the present study, data of susceptibility patterns of S. pyogenes isolates were retrieved from 2000 to 2019 with the aim to observe the emergence of resistance and to guide clinicians in prescription appropriateness. Materials and Methods: we collected a total of 4,958 unique S. pyogenes strains from positive samples, out of them 4,597 (93%) were from throat swabs, followed by vaginal swabs, skin swabs, blood cultures, and ear swabs. The median age of patients was 10 years (range 0-94 years). Results: the analysis was performed on the data collected from throat samples and blood cultures. In the isolates from throat specimens, except β-lactams and glycopeptides (vancomycin) which presented 100% of susceptibility, and tetracycline which presented an average resistance rate of 26%, all the other antibiotics tested showed significant increasing resistance trends: clindamycin 13-23%, erythromycin 29-35%, and levofloxacin 5-12% (p<0.01). About susceptibilities of isolates from blood cultures, although the low number of isolates, we observed 98-100% of susceptibility. Conclusions: although this work is single-center, national and regional active surveillance projects are needed to monitor antimicrobial resistance trends of S. pyogenes, and to help physicians in antibiotic prescription in subjects affected by acute or recurrent sore throats.
- Top Cited PapersOpen Access
- 7 February 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (2) , 283
Cefepime and New Cefepime/Beta-Lactamase Inhibitor Combination for the Treatment of Gram-Negative Bacteria: Chemical Structure and Mechanism of Action, Microbiological Target, Clinical Use and PK/PD Characteristics
The global spread of multidrug-resistant (MDR) Gram-negative bacteria, particularly extended-spectrum β-lactamase (ESBL)- and carbapenemase-producing Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii, presents a significant public health challenge by limiting effective antimicrobial treatment options. Cefepime, a fourth-generation cephalosporin with broad-spectrum activity, is increasingly compromised by β-lactamase production, efflux pumps, and porin loss. In response, novel cefepime-based β-lactam/β-lactamase inhibitor (BL/BLI) combinations have been developed to overcome these resistance mechanisms. This review examines preclinical and clinical studies on cefepime-based BL/BLI combinations, specifically cefepime/enmetazobactam, cefepime/taniborbactam, cefepime/zidebactam, and cefepime/nacubactam, as found in the PubMed database. Key findings include the restoration of activity against class A ESBLs with cefepime/enmetazobactam, while cefepime/taniborbactam and cefepime/zidebactam show broader inhibition of serine β-lactamases and selected metallo-β-lactamases. Additionally, zidebactam and nacubactam target penicillin-binding protein 2, enhancing bactericidal potency. Preclinical and early-phase clinical trial data indicate potent in vitro activity and favorable pharmacokinetic/pharmacodynamic (PK/PD) profiles. Specifically, the combination of cefepime with enmetazobactam has demonstrated an optimal Cmax/MIC ratio of 8–10, supporting its efficacy in treating MDR Gram-negative infections. Phase III studies are ongoing to confirm efficacy in complicated infections. Cefepime-based BL/BLI combinations are emerging as promising carbapenem-sparing agents, offering broad-spectrum activity, dual mechanisms of action, and encouraging clinical outcomes. These findings support their inclusion in antimicrobial stewardship strategies aimed at mitigating resistance.
- 7 February 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (2) , 283
Top Cited PapersOpen AccessCefepime and New Cefepime/Beta-Lactamase Inhibitor Combination for the Treatment of Gram-Negative Bacteria: Chemical Structure and Mechanism of Action, Microbiological Target, Clinical Use and PK/PD Characteristics
The global spread of multidrug-resistant (MDR) Gram-negative bacteria, particularly extended-spectrum β-lactamase (ESBL)- and carbapenemase-producing Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii, presents a significant public health challenge by limiting effective antimicrobial treatment options. Cefepime, a fourth-generation cephalosporin with broad-spectrum activity, is increasingly compromised by β-lactamase production, efflux pumps, and porin loss. In response, novel cefepime-based β-lactam/β-lactamase inhibitor (BL/BLI) combinations have been developed to overcome these resistance mechanisms. This review examines preclinical and clinical studies on cefepime-based BL/BLI combinations, specifically cefepime/enmetazobactam, cefepime/taniborbactam, cefepime/zidebactam, and cefepime/nacubactam, as found in the PubMed database. Key findings include the restoration of activity against class A ESBLs with cefepime/enmetazobactam, while cefepime/taniborbactam and cefepime/zidebactam show broader inhibition of serine β-lactamases and selected metallo-β-lactamases. Additionally, zidebactam and nacubactam target penicillin-binding protein 2, enhancing bactericidal potency. Preclinical and early-phase clinical trial data indicate potent in vitro activity and favorable pharmacokinetic/pharmacodynamic (PK/PD) profiles. Specifically, the combination of cefepime with enmetazobactam has demonstrated an optimal Cmax/MIC ratio of 8–10, supporting its efficacy in treating MDR Gram-negative infections. Phase III studies are ongoing to confirm efficacy in complicated infections. Cefepime-based BL/BLI combinations are emerging as promising carbapenem-sparing agents, offering broad-spectrum activity, dual mechanisms of action, and encouraging clinical outcomes. These findings support their inclusion in antimicrobial stewardship strategies aimed at mitigating resistance.
- Open Access
- 25 July 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (15) , 1599
Combined Use of Phenotypic Screening and of a Novel Commercial Assay (REALQUALITY Carba-Screen) for the Rapid Molecular Detection of Carbapenemases: A Single-Center Experience
Carbapenem resistance is a serious public health threat, causing numerous deaths annually primarily due to healthcare-associated infections. To face this menace, surveillance programs in high-risk patients are becoming a widespread practice. Here we report the performance of the combined use of a recently approved commercial multiplex real-time PCR assay (REALQUALITY Carba-Screen kit) with conventional phenotypic screening. In this three-month study, 479 rectal swabs from 309 patients across high-risk units were evaluated by combining the two approaches. Although the molecular assay showed a higher positivity rate than phenotypic screening (7.1% vs. 5%), it should be noted that the molecular method alone would have missed eight carbapenem-resistant isolates, while using only phenotypic screening would not have detected sixteen isolates. This demonstrates the complementary strengths of each method. Our study confirms the need for a combined approach to maximize the possible clinical impact of this kind of screening, ensuring a more comprehensive detection of resistant strains.
- 25 July 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (15) , 1599
Open AccessCombined Use of Phenotypic Screening and of a Novel Commercial Assay (REALQUALITY Carba-Screen) for the Rapid Molecular Detection of Carbapenemases: A Single-Center Experience
Carbapenem resistance is a serious public health threat, causing numerous deaths annually primarily due to healthcare-associated infections. To face this menace, surveillance programs in high-risk patients are becoming a widespread practice. Here we report the performance of the combined use of a recently approved commercial multiplex real-time PCR assay (REALQUALITY Carba-Screen kit) with conventional phenotypic screening. In this three-month study, 479 rectal swabs from 309 patients across high-risk units were evaluated by combining the two approaches. Although the molecular assay showed a higher positivity rate than phenotypic screening (7.1% vs. 5%), it should be noted that the molecular method alone would have missed eight carbapenem-resistant isolates, while using only phenotypic screening would not have detected sixteen isolates. This demonstrates the complementary strengths of each method. Our study confirms the need for a combined approach to maximize the possible clinical impact of this kind of screening, ensuring a more comprehensive detection of resistant strains.
- Open Access
- 5 March 2024
- Published by MDPI AG in Applied Microbiology
- Vol. 4 (1) , 481-485
Surveillance of Bacterial Meningitis in the Italian Hospital of Desio: A Twenty-Year Retrospective Study
Bacterial meningitis is a severe infection with a high fatality rate, and affects children in particular. Three vaccines against the most common bacterial causatives of meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, and Neisseria meningitides, exist. Monitoring the type and incidence of bacterial meningitis is important for making future prevention and control plans. In this study, we retrospectively analyzed data regarding bacterial meningitis recovered in the Italian Hospital of Desio from 2000 to 2019. Samples from a total of 128 patients were included. Streptococcus pneumoniae was the most common microorganism, isolated in 45 cases, followed by Neisseria meningitidis (14), Listeria monocytogenes (8), Streptococcus agalactiae (group B) (4), and Haemophilus influenzae type b (2). The implementation of vaccination schedules decreased the number of bacterial meningitis cases caused by H. influenzae type b, S. pneumoniae, and N. meningitidis. Considering the bacterial meningitis cases in subjects aged 0–12 years, no H. influenzae type b strain was isolated, five cases of N. meningitidis were identified before the introduction of vaccination, and seven S. pneumoniae strains were isolated before the introduction of the PCV13 vaccination. Surveillance studies allowed us to monitor changes in bacteria distribution and to guide vaccination strategies.
- 5 March 2024
- Published by MDPI AG in Applied Microbiology
- Vol. 4 (1) , 481-485
Open AccessSurveillance of Bacterial Meningitis in the Italian Hospital of Desio: A Twenty-Year Retrospective Study
Bacterial meningitis is a severe infection with a high fatality rate, and affects children in particular. Three vaccines against the most common bacterial causatives of meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, and Neisseria meningitides, exist. Monitoring the type and incidence of bacterial meningitis is important for making future prevention and control plans. In this study, we retrospectively analyzed data regarding bacterial meningitis recovered in the Italian Hospital of Desio from 2000 to 2019. Samples from a total of 128 patients were included. Streptococcus pneumoniae was the most common microorganism, isolated in 45 cases, followed by Neisseria meningitidis (14), Listeria monocytogenes (8), Streptococcus agalactiae (group B) (4), and Haemophilus influenzae type b (2). The implementation of vaccination schedules decreased the number of bacterial meningitis cases caused by H. influenzae type b, S. pneumoniae, and N. meningitidis. Considering the bacterial meningitis cases in subjects aged 0–12 years, no H. influenzae type b strain was isolated, five cases of N. meningitidis were identified before the introduction of vaccination, and seven S. pneumoniae strains were isolated before the introduction of the PCV13 vaccination. Surveillance studies allowed us to monitor changes in bacteria distribution and to guide vaccination strategies.
- Open Access
- 15 September 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (9) , 1304
New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians
Antibiotic resistance is a public health problem with increasingly alarming data being reported. Gram-positive bacteria are among the protagonists of severe nosocomial and community infections. The objective of this review is to conduct an extensive examination of emerging treatments for Gram-positive infections including ceftobiprole, ceftaroline, dalbavancin, oritavancin, omadacycline, tedizolid, and delafloxacin. From a methodological standpoint, a comprehensive analysis on clinical trials, molecular structure, mechanism of action, microbiological targeting, clinical use, pharmacokinetic/pharmacodynamic features, and potential for therapeutic drug monitoring will be addressed. Each antibiotic paragraph is divided into specialized microbiological, clinical, and pharmacological sections, including detailed and appropriate tables. A better understanding of the latest promising advances in the field of therapeutic options could lead to the development of a better approach in managing antimicrobial therapy for multidrug-resistant Gram-positive pathogens, which increasingly needs to be better stratified and targeted.
- 15 September 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (9) , 1304
Open AccessNew Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians
Antibiotic resistance is a public health problem with increasingly alarming data being reported. Gram-positive bacteria are among the protagonists of severe nosocomial and community infections. The objective of this review is to conduct an extensive examination of emerging treatments for Gram-positive infections including ceftobiprole, ceftaroline, dalbavancin, oritavancin, omadacycline, tedizolid, and delafloxacin. From a methodological standpoint, a comprehensive analysis on clinical trials, molecular structure, mechanism of action, microbiological targeting, clinical use, pharmacokinetic/pharmacodynamic features, and potential for therapeutic drug monitoring will be addressed. Each antibiotic paragraph is divided into specialized microbiological, clinical, and pharmacological sections, including detailed and appropriate tables. A better understanding of the latest promising advances in the field of therapeutic options could lead to the development of a better approach in managing antimicrobial therapy for multidrug-resistant Gram-positive pathogens, which increasingly needs to be better stratified and targeted.
- Open Access
- 18 April 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (4) , 775
Antimicrobial Resistance Patterns of Enterobacter cloacae and Klebsiella aerogenes Strains Isolated from Clinical Specimens: A Twenty-Year Surveillance Study
We retrospectively analyzed the antimicrobial data of Enterobacter spp. strains isolated from hospitalized subjects and outpatients over 20 years (2000–2019). A total of 2277 non-duplicate Enterobacter spp. isolates, 1037 from outpatients (45%) and 1240 from hospitalized subjects (55%), were retrieved. Most of samples are infections of the urinary tract. Considering Enterobacter aerogenes, now classified as Klebsiella aerogenes, and Enterobacter cloacae, representing more than 90% of all isolates, except for aminoglycosides and fluroquinolones, which showed significant antibiotic decreasing trends (p < 0.01), none of the other antimicrobial agents tested showed significant changes in both groups (p > 0.05). Conversely, there was a significant increasing resistance trend for fosfomycin (p < 0.01), among both community and hospital-related subjects, most probably owing to uncontrolled and improper usage. Surveillance studies on antibiotic resistance at the local and regional level are required to detect new resistance mechanisms, reduce inappropriate antimicrobial consumption, and increase the focus on antimicrobial stewardship.
- 18 April 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (4) , 775
Open AccessAntimicrobial Resistance Patterns of Enterobacter cloacae and Klebsiella aerogenes Strains Isolated from Clinical Specimens: A Twenty-Year Surveillance Study
We retrospectively analyzed the antimicrobial data of Enterobacter spp. strains isolated from hospitalized subjects and outpatients over 20 years (2000–2019). A total of 2277 non-duplicate Enterobacter spp. isolates, 1037 from outpatients (45%) and 1240 from hospitalized subjects (55%), were retrieved. Most of samples are infections of the urinary tract. Considering Enterobacter aerogenes, now classified as Klebsiella aerogenes, and Enterobacter cloacae, representing more than 90% of all isolates, except for aminoglycosides and fluroquinolones, which showed significant antibiotic decreasing trends (p < 0.01), none of the other antimicrobial agents tested showed significant changes in both groups (p > 0.05). Conversely, there was a significant increasing resistance trend for fosfomycin (p < 0.01), among both community and hospital-related subjects, most probably owing to uncontrolled and improper usage. Surveillance studies on antibiotic resistance at the local and regional level are required to detect new resistance mechanisms, reduce inappropriate antimicrobial consumption, and increase the focus on antimicrobial stewardship.
- Open Access
- 6 June 2022
- Published by MDPI AG in Microorganisms
- Vol. 10 (6) , 1163
Lack of Direct Correlation between Biofilm Formation and Antimicrobial Resistance in Clinical Staphylococcus epidermidis Isolates from an Italian Hospital
Staphylococcus epidermidis is an opportunistic pathogen and a frequent cause of nosocomial infections. In this work, we show that, among 51 S. epidermidis isolates from an Italian hospital, only a minority displayed biofilm formation, regardless of their isolation source (peripheral blood, catheter, or skin wounds); however, among the biofilm-producing isolates, those from catheters were the most efficient in biofilm formation. Interestingly, most isolates including strong biofilm producers displayed production levels of PIA (polysaccharide intercellular adhesin), the main S. epidermidis extracellular polysaccharide, similar to reference S. epidermidis strains classified as non-biofilm formers, and much lower than those classified as intermediate or high biofilm formers, possibly suggesting that high levels of PIA production do not confer a particular advantage for clinical isolates. Finally, while for the reference S. epidermidis strains the biofilm production clearly correlated with the decreased sensitivity to antibiotics, in particular, protein synthesis inhibitors, in our clinical isolates, such positive correlation was limited to tetracycline. In contrast, we observed an inverse correlation between biofilm formation and the minimal inhibitory concentrations for levofloxacin and teicoplanin. In addition, in growth conditions favoring PIA production, the biofilm-forming isolates showed increased sensitivity to daptomycin, clindamycin, and erythromycin, with increased tolerance to the trimethoprim/sulfamethoxazole association. The lack of direct correlation between the biofilm production and increased tolerance to antibiotics in S. epidermidis isolates from a clinical setting would suggest, at least for some antimicrobials, the possible existence of a trade-off between the production of biofilm determinants and antibiotic resistance.
- 6 June 2022
- Published by MDPI AG in Microorganisms
- Vol. 10 (6) , 1163
Open AccessLack of Direct Correlation between Biofilm Formation and Antimicrobial Resistance in Clinical Staphylococcus epidermidis Isolates from an Italian Hospital
Staphylococcus epidermidis is an opportunistic pathogen and a frequent cause of nosocomial infections. In this work, we show that, among 51 S. epidermidis isolates from an Italian hospital, only a minority displayed biofilm formation, regardless of their isolation source (peripheral blood, catheter, or skin wounds); however, among the biofilm-producing isolates, those from catheters were the most efficient in biofilm formation. Interestingly, most isolates including strong biofilm producers displayed production levels of PIA (polysaccharide intercellular adhesin), the main S. epidermidis extracellular polysaccharide, similar to reference S. epidermidis strains classified as non-biofilm formers, and much lower than those classified as intermediate or high biofilm formers, possibly suggesting that high levels of PIA production do not confer a particular advantage for clinical isolates. Finally, while for the reference S. epidermidis strains the biofilm production clearly correlated with the decreased sensitivity to antibiotics, in particular, protein synthesis inhibitors, in our clinical isolates, such positive correlation was limited to tetracycline. In contrast, we observed an inverse correlation between biofilm formation and the minimal inhibitory concentrations for levofloxacin and teicoplanin. In addition, in growth conditions favoring PIA production, the biofilm-forming isolates showed increased sensitivity to daptomycin, clindamycin, and erythromycin, with increased tolerance to the trimethoprim/sulfamethoxazole association. The lack of direct correlation between the biofilm production and increased tolerance to antibiotics in S. epidermidis isolates from a clinical setting would suggest, at least for some antimicrobials, the possible existence of a trade-off between the production of biofilm determinants and antibiotic resistance.
- Open Access
- 12 April 2022
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (4) , 463
Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians
Bacterial resistance mechanisms are continuously and rapidly evolving. This is particularly true for Gram-negative bacteria. Over the last decade, the strategy to develop new β-lactam/β-lactamase inhibitors (BLs/BLIs) combinations has paid off and results from phase 3 and real-world studies are becoming available for several compounds. Cefiderocol warrants a separate discussion for its peculiar mechanism of action. Considering the complexity of summarizing and integrating the emerging literature data of clinical outcomes, microbiological mechanisms, and pharmacokinetic/pharmacodynamic properties of the new BL/BLI and cefiderocol, we aimed to provide an overview of data on the following compounds: aztreonam/avibactam, cefepime/enmetazobactam, cefepime/taniborbactam, cefepime/zidebactam, cefiderocol, ceftaroline/avibactam, ceftolozane/tazobactam, ceftazidime/avibactam, imipenem/relebactam, meropenem/nacubactam and meropenem/vaborbactam. Each compound is described in a dedicated section by experts in infectious diseases, microbiology, and pharmacology, with tables providing at-a-glance information.
- 12 April 2022
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (4) , 463
Open AccessMicrobiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians
Bacterial resistance mechanisms are continuously and rapidly evolving. This is particularly true for Gram-negative bacteria. Over the last decade, the strategy to develop new β-lactam/β-lactamase inhibitors (BLs/BLIs) combinations has paid off and results from phase 3 and real-world studies are becoming available for several compounds. Cefiderocol warrants a separate discussion for its peculiar mechanism of action. Considering the complexity of summarizing and integrating the emerging literature data of clinical outcomes, microbiological mechanisms, and pharmacokinetic/pharmacodynamic properties of the new BL/BLI and cefiderocol, we aimed to provide an overview of data on the following compounds: aztreonam/avibactam, cefepime/enmetazobactam, cefepime/taniborbactam, cefepime/zidebactam, cefiderocol, ceftaroline/avibactam, ceftolozane/tazobactam, ceftazidime/avibactam, imipenem/relebactam, meropenem/nacubactam and meropenem/vaborbactam. Each compound is described in a dedicated section by experts in infectious diseases, microbiology, and pharmacology, with tables providing at-a-glance information.